News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Philogen S.p.A. IPO Pulled as Bayer Corporation Exits Cancer Pact
February 15, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- An eagerly-anticipated initial public offering by the Swiss-Italian biotech Philogen has been cancelled at the last minute after partner Bayer pulled out of their oncology collaboration.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Bayer
MORE ON THIS TOPIC
Deals
Boehringer Links with Irish Drug Delivery Start-Up Re-Vana in $1B+ Eye Deal
July 28, 2025
·
1 min read
·
Dan Samorodnitsky
Deals
GSK Bets Up To $12B for Multi-Program Cancer Pact With Hengrui
July 28, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Eli Lilly Commits $856M in Biobucks to Gate Bioscience for New Class of Medicines
July 25, 2025
·
1 min read
·
Dan Samorodnitsky
I&I
Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint
July 24, 2025
·
2 min read
·
Dan Samorodnitsky
